Reaction

Cytolytic Hepatitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,326 reports · 115 co-occurring drugs

As of the last recalculation, Cytolytic Hepatitis appears in 3,326 FAERS reports alongside 115 co-occurring drug terms. The strongest observed disproportionality signal is RIFAMPICIN (PRR 39.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Rifampicin	63	39.7	39.9
Lopinavir And Ritonavir	59	27.7	27.8
Ritonavir	111	24.6	24.6
Atazanavir	52	23.0	23.1
Ketoprofen	47	22.7	22.8
Raltegravir	43	16.5	16.5
Anti-Thymocyte Globulin (Rabbit)	21	16.4	16.4
Fondaparinux Sodium	18	14.0	14.0
Gentamicin	28	13.5	13.5
Enoxaparin Sodium	119	13.4	13.4
Gentamicin Sulfate	32	12.8	12.8
Darunavir	30	12.5	12.5
Emtricitabine And Tenofovir Disoproxil Fumarate	86	12.1	12.1
Fosaprepitant Dimeglumine	26	11.9	11.9
Desloratadine	20	11.7	11.8
Amoxicillin And Clavulanate Potassium	49	11.4	11.5
Lamivudine	54	11.1	11.1
Abacavir Sulfate	17	11.0	11.0
Sulfamethoxazole And Trimethoprim	140	10.8	10.8
Esomeprazole Magnesium Capsule, Delayed Release	24	10.4	10.4
Esomeprazole Magnesium Delayed Release Capsules	24	10.4	10.4
Esomeprazole Magnesium Dihydrate	24	10.4	10.4
Piperacillin And Tazobactam	21	10.3	10.3
Methylprednisolone Sodium Succinate	74	10.2	10.2
Aprepitant	27	9.2	9.2
Imatinib Mesylate	40	9.1	9.1
Gefitinib	13	9.0	9.1
Posaconazole	22	8.5	8.5
Levothyroxine Sodium Anhydrous	127	8.2	8.2
Propofol	47	8.2	8.2
Piperacillin Sodium And Tazobactam Sodium	24	7.7	7.7
Voriconazole	37	7.7	7.7
Colchicine	32	7.7	7.7
Tenofovir Disoproxil Fumarate	40	7.7	7.7
Mesna Injection	10	7.6	7.6
Zidovudine	16	7.5	7.5
Mesna	10	7.5	7.5
Dronedarone	12	7.4	7.4
Candesartan Cilexetil	30	7.2	7.2
Esomeprazole Magnesium	250	7.1	7.2
Amikacin	19	7.0	7.0
Nevirapine	10	7.0	7.0
Pyrazinamide	10	6.7	6.7
Sucralfate Oral	15	6.6	6.6
Sucralfate Oral Suspension	15	6.6	6.6
Iron Sucrose	10	6.6	6.6
Bosentan	52	6.5	6.5
Busulfan	16	6.4	6.4
Vancomycin	58	6.4	6.4
Atorvastatin Calcium, Film Coated	69	6.3	6.3
Rabeprazole	22	6.2	6.3
Vancomycin Hydrochloride	64	6.2	6.2
Carbamazepine	65	6.2	6.2
Primidone	10	6.2	6.2
Sevoflurane	8	6.0	6.0
Rivastigmine	18	6.0	6.0
Acetaminophen Tablet Extended Release	230	6.0	6.0
Pain Reliever	230	6.0	6.0
Acetaminophen 500Mg	230	6.0	6.0
Itraconazole	11	5.9	5.9
Oxazepam	20	5.8	5.9
Levocetirizine Dihydrochloride	22	5.8	5.8
Pravastatin Sodium	18	5.7	5.7
Posaconazole Delayed-Release	10	5.7	5.7
Divalproex Sodium	42	5.7	5.7
Olanzapine Pamoate	35	5.4	5.4
Irbesartan	38	5.4	5.4
Bicalutamide	13	5.4	5.4
Hydroxyurea	18	5.4	5.4
Acetylcysteine	8	5.3	5.3
Indapamide	15	5.3	5.3
Rabeprazole Sodium	22	5.1	5.1
Cytarabine	48	5.1	5.1
Ritonavir 100 Mg	12	5.0	5.0
Esomeprazole	49	5.0	5.0
Piperacillin Sodium,Tazobactam Sodium	21	5.0	5.0
Lamivudine Oral	20	5.0	5.0
Escitalopram Oxalate	57	5.0	5.0
Clarithromycin	27	5.0	5.0
Metformin Hcl	42	4.8	4.8
Cetirizine Hcl	7	4.8	4.8
Fenofibrate	26	4.6	4.6
Heparin Sodium	10	4.6	4.6
Amphotericin B	9	4.5	4.5
Efavirenz	8	4.5	4.5
Sunitinib Malate	28	4.5	4.5
Diltiazem Hydrochloride Extended-Release Tablets	8	4.4	4.4
Oxcarbazepine	22	4.3	4.3
Escitslopram	39	4.2	4.2
Atenolol	88	4.2	4.2
Memantine	9	4.1	4.1
Memantine Hydrochloride	9	4.1	4.1
Dorzolamide Hydrochloride And Timolol Maleate	5	4.0	4.0
Isoniazid	10	3.9	3.9
Levetiracetam	81	3.9	3.9
Linezolid	18	3.8	3.8
Anakinra	10	3.8	3.8
Clopidogrel	114	3.7	3.7
Lisinopril And Hydrochlorothiazide	6	3.7	3.7
Bleomycin Sulfate	6	3.6	3.6
Tenofovir Disoproxil Fumarate Tablets	5	3.6	3.6
Deferasirox	15	3.6	3.6
Ibuprofen Tablets, Coated	24	3.6	3.6
Ibuprofen Sodium	24	3.5	3.5
Donepezil Hydrochloride	20	3.4	3.4
Pemetrexed Disodium	20	3.3	3.3
Bendamustine Hydrochloride	6	3.1	3.1
Micafungin Sodium	4	3.0	3.0
Risperidone	60	2.9	2.9
Lapatinib	7	2.8	2.8
Oseltamivir Phosphate	11	2.8	2.8
Entecavir	5	2.7	2.7
Peginterferon Alfa-2A	23	2.7	2.7
Crizotinib	4	2.0	2.0
Cetuximab	9	1.8	1.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.